Scientific American

How scientists made the discoveries behind a game-changing gene therapy for sickle cell disease

Stuart Orkin and Swee Lay Thein shared a Breakthrough Prize in Life Sciences for their research on genetic causes of sickle ...
University of California, San Francisco

Love Family Gives $2.5M to Advance Sickle Cell Care at UCSF

A $2.5 million gift by Ted W. Love and Joyce Y. Love to UCSF Benioff Children’s Hospitals will expand care for patients with ...
European Medical Journal

CRISPR Gene Therapy Shows Promise in Sickle Cell Disease

CRISPR gene therapy increases haemoglobin and fetal haemoglobin in sickle cell disease, reducing vaso occlusive events in ...
NOLA.com

First Louisiana patient to receive sickle cell gene therapy heads home after 6 weeks in hospital

Learn about the groundbreaking gene therapy for sickle cell disease at Manning Family Children's Hospital in Louisiana, ...
Healio

Advanced gene editing ‘promising’ for sickle cell disease, but access challenges remain

Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...
European Medical Journal

Novel Conditioning Regimen Improves Sickle Cell Transplant Outcomes

Novel conditioning regimen improves survival and engraftment in sickle cell transplant patients with low graft versus host ...

Sickle cell disease patients at Long Island hospitals had highest risk of dying, study finds

About 10% of people hospitalized with sickle cell on Long Island between 2009 and 2022 faced a "major risk of mortality," ...

Louisiana’s 1st sickle cell gene therapy patient heads home after historic treatment

After six weeks in the hospital, 23‑year‑old Daniel Cressy leaves with hope for a functional cure and a future where he can ...
Newsweek

Patients With Disease That Causes ‘Worst Pain’ Often Triaged Wrongly

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Most patients living with sickle cell disease who went to the emergency ...

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis ...

Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on ...
News-Medical.Net

Sickle cell disease care is unevenly distributed across regions in New York State

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. Approximately 10 percent of ...